GEHC GE HealthCare Technologies Inc.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus · Nasdaq · SEC CIK 1932393 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.9%
TTM net income YoY-2.8%
TTM EPS YoY-2.1%
Revenue 3-yr CAGR3.9%
Net income 3-yr CAGR7.8%
Margins
Gross margin39.9%
Operating margin13.3%
Net margin10.0%
FCF margin8.7%
EBITDA margin14.8%
Returns
ROE19.9%
ROA5.8%
ROIC (approx.)13.2%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets69.1%
Debt / equity0.86x
Current ratio1.30x
Interest coverage6.60x
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio-0.7%
Payout ratio3.0%
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.51B | $5.29B | $5.13B | $5.70B | $5.14B | $5.01B | $4.78B | $5.32B |
| Gross profit | $2.22B | $2.18B | $1.98B | $2.26B | $1.99B | $1.99B | $2.01B | $2.27B |
| R&D expense | $320.00M | $323.00M | $345.00M | $323.00M | $292.00M | $302.00M | $344.00M | $344.00M |
| SG&A expense | $1.10B | $1.12B | $1.12B | $1.11B | $1.04B | $1.03B | $1.04B | $1.13B |
| Operating income | $805.00M | $739.00M | $515.00M | $827.00M | $653.00M | $654.00M | $629.00M | $801.00M |
| Interest expense | $122.00M | $114.00M | $96.00M | $105.00M | $111.00M | $113.00M | $110.00M | $121.00M |
| Pretax income | $752.00M | $693.00M | $505.00M | $821.00M | $643.00M | $613.00M | $692.00M | $834.00M |
| Income tax | $129.00M | $119.00M | $94.00M | $219.00M | $179.00M | $113.00M | $104.00M | $96.00M |
| Net income | $615.00M | $561.00M | $389.00M | $589.00M | $446.00M | $486.00M | $564.00M | $721.00M |
| EBITDA | $886.00M | $815.00M | $593.00M | $901.00M | $728.00M | $727.00M | $695.00M | $866.00M |
| EPS (basic) | 1.36 | 1.24 | 0.85 | — | 0.98 | 1.06 | 1.23 | — |
| EPS (diluted) | 1.36 | 1.24 | 0.85 | — | 0.98 | 1.06 | 1.23 | — |
| Dividends declared per share | 0.04 | 0.04 | 0.04 | 0.04 | 0.07 | 0.00 | 0.04 | 0.04 |
| Weighted avg. shares (diluted) | 453.00M | 454.00M | 457.00M | — | 457.00M | 458.00M | 459.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.83B | $2.08B | $2.26B | $4.49B | $4.03B | $3.77B | $2.48B | $2.89B |
| Inventory | $2.63B | $2.48B | $2.35B | $2.23B | $2.30B | $2.28B | $2.16B | $1.94B |
| Current assets | $11.49B | $10.50B | $10.43B | $12.50B | $11.89B | $11.31B | $9.73B | $9.90B |
| Goodwill | $15.14B | $15.10B | $15.06B | $13.49B | $13.44B | $13.42B | $13.37B | $13.14B |
| Intangibles | $1.81B | $1.89B | $1.91B | $1.13B | $1.16B | $1.22B | $1.24B | $1.08B |
| Total assets | $38.37B | $37.25B | $37.12B | $36.91B | $36.13B | $35.50B | $33.59B | $33.09B |
| Current liabilities | $8.81B | $8.30B | $8.53B | $9.11B | $10.07B | $9.75B | $9.97B | $9.55B |
| Short-term debt | $2.00M | $2.00M | $2.00M | $502.00M | $2.00B | $2.00B | $2.00B | $1.50B |
| Long-term debt | $9.97B | $10.09B | $10.13B | $9.49B | $8.28B | $8.27B | $6.76B | $7.45B |
| Total debt | $9.97B | $10.09B | $10.13B | $10.00B | $10.28B | $10.27B | $8.76B | $8.95B |
| Total liabilities | $26.51B | $26.03B | $26.23B | $26.31B | $25.91B | $25.55B | $24.17B | $24.44B |
| Shareholders' equity | $11.61B | $10.97B | $10.67B | $10.38B | $9.99B | $9.71B | $9.19B | $8.45B |
| Net debt | $7.15B | $8.01B | $7.87B | $5.50B | $6.25B | $6.51B | $6.28B | $6.06B |
| Cash flow statement | ||||||||
| Operating cash flow | $907.00M | $168.00M | $290.00M | $1.05B | $593.00M | $94.00M | $250.00M | $913.00M |
| Capital expenditure | $114.00M | $100.00M | $178.00M | $134.00M | $110.00M | $86.00M | $152.00M | $102.00M |
| Free cash flow | $793.00M | $68.00M | $112.00M | $916.00M | $483.00M | $8.00M | $98.00M | $811.00M |
| Investing cash flow | -$111.00M | -$115.00M | -$2.50B | -$269.00M | -$148.00M | -$223.00M | -$407.00M | -$240.00M |
| Financing cash flow | -$40.00M | -$236.00M | $21.00M | -$293.00M | -$165.00M | $1.36B | -$286.00M | -$1.28B |
| Depreciation & amortization | $81.00M | $76.00M | $78.00M | $74.00M | $75.00M | $73.00M | $66.00M | $65.00M |
| Stock-based compensation | $36.00M | $45.00M | $35.00M | $36.00M | $38.00M | $34.00M | $22.00M | $33.00M |
| Dividends paid | $16.00M | $16.00M | $16.00M | $16.00M | $16.00M | $16.00M | $16.00M | $14.00M |
| Share buybacks | $0 | $200.00M | $100.00M | $0 | $100.00M | $100.00M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.